Welcome to today's Biotech Spotlight series, which focuses on companies creating breakthrough technologies and products. This edition highlights 4D Molecular Therapeutics (4DMT), a biotechnology company using cutting-edge evolutionary methods to advance gene therapy into a new phase.

Just a few years ago, gene therapy was still an emerging field in the biopharmaceutical industry. Today, its trajectory shows almost no ceiling, with companies like 4D Molecular Therapeutics working on treatments that could change how we think about genetic medicine.

With the addition of University of California, San Francisco (UCSF) professor Dr. Noriyuki Kasaharaand a partnership with fellow gene therapy pioneer Arbor Biotechnologies, 4DMT is carving out new footholds on the "cliffs" of gene therapy through novel viral vector-based delivery methods.

4DMT's advanced computational discovery system can precisely identify subtle variations in the genome that cause diseases such as diabetes and heart disease. To reach the root of these complex diseases, the company employs a method called "directed evolution"—finding the "needle in the haystack" and guiding gene therapy to correct it.

4DMT CEO Dr. David Kirn says the key to gene therapy lies in delivery, and 4DMT's technology is designed to keep delivery methods in step with industry needs. Below is our conversation with Kirn about the future of gene therapy and why improving delivery is so important.

This interview has been edited for length and style.

PHARMAVOICE: Why does the industry need to find new ways to use gene therapy?

Dr. David Kirn: Simply put, people usually understand gene therapy as treating a disease caused by a missing gene, such as muscular dystrophy or cystic fibrosis—conditions caused by a single gene mutation, where the idea is to package a normal copy of the gene into a vector and deliver it to the tissues and cells that need repair. That description sounds very simple—the beauty of the concept lies in its simplicity—but its application goes far beyond replacing mutated genes in monogenic recessive disorders. We believe that, with a flexible approach, it can also serve broader markets beyond rare genetic diseases.

When I entered this field, I asked a colleague what the biggest problem in gene therapy was. He replied that there were only three: delivery, delivery, and delivery. The concept itself is simple; the challenge is how to achieve delivery. The field started somewhat naively—people thought they could just throw these (genes) into cells, but that is extremely inefficient. So, the bottleneck has always been delivery, and our platform is designed to overcome these bottlenecks.

How has your platform evolved to address these issues?

We use what is called "directed evolution." This is a technique for creating or inventing customized biological agents with desired traits, which earned Frances Arnold of Caltech the Nobel Prize in Chemistry in 2018, when she applied it to enzymes. Her idea was: if I generate a large number of different versions of an enzyme, then screen and select the one that matches my desired phenotype, I can invent a new optimized factor for any condition I want to optimize. Later, Greg Winters and George Smith applied it to monoclonal antibodies and phages. This opened up the idea that we can go beyond biological agents found in nature and invent entirely new ones with the traits we want. We are the first team to apply this concept to [adeno-associated virus] vectors.

How do you view the future of gene therapy?

The key is to use techniques like directed evolution to continuously optimize and improve methods so they can go beyond a few rare diseases and begin to impact countless patients. The starting point is very niche areas where delivery requirements are low and product approval is still achievable, and what we are trying to do is elevate it to a whole new level, making it one of the core pillars of healthcare. The future of gene therapy is selecting, from billions of possibilities, that optimal "needle in the haystack" for the target vector.

What does your day-to-day work look like as you prepare for communications with the FDA?

This is an extremely exciting time—a turning point. Within 10 years, we have advanced 5 products to the clinical stage and patented hundreds of different optimized vectors. Now we have proven that these vectors perform as expected, and the key is to create a superior vector that can overcome the limitations of older ones.